Literature DB >> 9361156

Methotrexate use in psoriasis and psoriatic arthritis.

M L Cuellar1, L R Espinoza.   

Abstract

Methotrexate is an extremely effective drug in the treatment of psoriasis and psoriatic arthritis. In addition, it possesses a very high benefit-to-toxicity ratio compared with other therapies and immunosuppressive agents used in these disorders. Fortunately, most adverse events related to methotrexate are mild, but serious and life-threatening reactions, particularly liver toxicity, may occur. Careful monitoring is essential to prevent most undesirable side effects.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9361156     DOI： 10.1016/s0889-857x(05)70361-6

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN： 0889-857X            Impact factor:   2.670


  4 in total

1.  Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up.

Authors:  E Kruithof; F Van den Bosch; D Baeten; A Herssens; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

Review 2.  Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.

Authors:  F Van den Bosch; D Baeten; E Kruithof; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

3.  Effect of methotrexate on neuroepithelium in the rat fetal brain.

Authors:  Jing Sun; Akihiko Sugiyama; Shota Inoue; Takashi Takeuchi; Satoshi Furukawa
Journal:  J Vet Med Sci       Date:  2013-11-08       Impact factor: 1.267

4.  Effect of methotrexate exposure at late gestation on development of telencephalon in rat fetal brain.

Authors:  Ayano Hirako; Satoshi Furukawa; Takashi Takeuchi; Akihiko Sugiyama
Journal:  J Vet Med Sci       Date:  2015-09-13       Impact factor: 1.267
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.